

Equity Research

March 10, 2014

**Price: \$34.35** (03/7/2014)

**Price Target: \$55.00**

**OUTPERFORM (1)**

**Ken Cacciatore**

646.562.1305

ken.cacciatore@cowen.com

**Anant Padmanabhan, CFA**

646.562.1374

anant.padmanabhan@cowen.com

**Tyler Van Buren, M.Sc.**

646.562.1338

tyler.vanburen@cowen.com

**Key Data**

Symbol [NASDAQ: RVNC](#)

Market Cap (MM) [\\$640.4](#)

Company Quick Take

## *RT-002 Data To Be Announced This Spring Could Prove Exceedingly Interesting*

### **The Cowen Insight**

RT-002 is a long-acting injectable botulinum toxin which could be disruptive in the therapeutic treatment market. Importantly, Phase I/II duration data should be announced this spring – and although small scale and early – could prove exceedingly interesting. In fact, we believe this product could ultimately prove transformational to the treatment paradigm. We would add here.

### **RT-002 Data Should Be Available Within A Few Months**

Following a meeting with management we wanted to highlight their RT-002 program (long-acting injectable botulinum toxin), which receives significantly less focus than RT-001, Revance's topical botulinum toxin. This is understandable, as the data for this program has been limited to date. However, this is about to change as results from the ongoing Phase I/II 48 patient RT-002 study – which has a 12 patient cohort to show duration – should be announced this spring. We believe a duration of action 50% greater (6+ months) compared to Botox (at 3-4 months) would be significant, and potentially allow for RT-002 to be disruptive in the current neurotoxin injectable marketplace. Following results of this study – if positive – Revance is planning to initiate a head-to-head study comparing the durability of RT-002 versus Allergan's Botox. Given its potential disruptive potential, we wonder (aloud) whether Allergan could afford to let such a head-to-head study read-out without owning the program. We also wonder (aloud) whether RT-002 could be used in the therapeutic indications to finally achieve the appropriate price differential between the Botox aesthetic market (where Allergan could leave that product in that setting) and use RT-002 in the therapeutic market where having a longer-duration option would likely be very well received by neurologists/patients by minimizing visits and extending efficacy. For perspective, we estimate that U.S. Botox Therapeutic sales will reach nearly \$850-900MM in 2014 (out of the total global Botox Therapeutic estimate of \$1,250MM). Given the inability to price differentiate the product in this reimbursed setting because of the availability of the same product in the private pay aesthetic market, the value for the franchise likely could be 2x higher, or an additional/incremental \$850-900MM in the U.S. alone if finally appropriately priced. Allergan indicates that they have several other botulinum programs in development (potentially even a long-acting option) but information on these products has been limited to date. And whether Allergan has such programs is – to a certain extent – irrelevant, given that if Revance could be faster to market with a differentiated duration product it would be able to establish a first mover advantage that other competitors (Valeant, Johnson & Johnson, GlaxoSmithKline, just to name a few) would likely very much covet, in our view. The bottom-line is that we can easily envision a scenario where the RT-002 program creates value not only for Revance, but potentially creates significant value for Allergan which would not only be protecting its single most important (and still growing franchise) – but could actually enhance its value. What would a program

like this be worth to both protect, extend – and create additional value? A lot, we believe.

While we caution that the information/data that we currently have on RT-002 is exceedingly early, we believe that there are some interesting observations that can be made. In the first Phase I/II RT-002 study conducted that confirmed efficacy, an effect was qualitatively observed in a study patient up to 7 months (+75-133% longer acting). In rodent studies, effects +58-126% longer than Botox were observed. Although these initial proof of concept studies for RT-002 (described on later pages within this note) are in the cosmetic setting, we believe it ultimately could prove transformative for therapeutic treatment where fewer clinician visits for such treatments as spasticity/stroke, cervical dystonias, and migraine, would be very well received. And, as indicated above, if there is success in this program, we believe that this asset would look exceedingly attractive to other manufacturers (those already with an injectable and therefore seeking to protect their franchise, as well as to those that would like to enter this very lucrative market).

#### **Multiple Scenarios Argue For Higher Valuation From These Levels**

Assuming clinical success and a reasonable RT-001 penetration rate, we arrive at a base valuation of \$55 per share. This assumes that Revance embarks upon its own marketing/promotional effort, which we believe this management team is very well equipped to do. Alternatively, a potential acquirer with its own commercial infrastructure — which would significantly lower our spending assumptions in the DCF — would argue for a valuation of the RT001 opportunity alone of \$80. And if combined with successful development for RT002 would provide for a transformational valuation in excess of \$100+. Given these potential outcomes, we would be adding at these levels.

On the following pages is more information on the limited data to date on the RT-002 program.

## RT002 Could Have Significant Implications For Therapeutic Indications

Although the initial proof of concept studies for RT002 are in the cosmetic setting, we believe it ultimately could prove transformative for utilization for therapeutic treatment where fewer clinician visits for such treatments as spasticity/stroke, cervical dystonias, and migraine would be well received. And if there is success in this program, we believe that this asset would look exceedingly attractive to other manufacturers (both already on the market with an injectable, as well as to those that would like to enter the space). Given the early nature of the development, we have excluded this product from our current model, but believe it holds exceedingly interesting promise. Interestingly, Phase I data with a 12-patient cohort (out of a 48 patient total study) analyzing the product's duration should be announced this spring, which should provide early perspectives on the profile.

If success in this study is achieved and a duration significantly longer than Botox is confirmed, we believe Allergan simply would have to acquire Revance to neutralize the threat to the Company's cornerstone Botox franchise. In fact, this could finally allow Allergan to achieve differentiated pricing for therapeutic versus cosmetic indications, which they have already been pursuing as evidenced by the Company suing HHS. If Allergan is finally able to increase pricing for therapeutic indications, we believe the price increase could be substantial (i.e. 2-3x), since it can be reimbursed for these more serious health conditions as opposed to having patients pay out of pocket.

### RT002, A "Next Generation" Injectable Toxin With A Potential Longer Duration Of Action, Which Could Be Disruptive To Existing Neurotoxin Injectables

Essentially, instead of having to be reinjected every 3-4 months, RT002 could increase that time period to potentially every 6-7 months. If Revance is able to achieve this in the Phase I/II study to report out in the next few months, we – and our physician consultants – agree that this product could be highly disruptive to the existing \$2.7B global neurotoxin injectable marketplace and command a significant share in a swift manner.


RT002 is Revance's second drug candidate and with it, the Company hopes to demonstrate at least a 50% longer duration of action relative to existing injectable neurotoxin treatments (Botox, Dysport, Xeomin). Serendipitously, the Company noticed that when the peptide-conjugated botulinum toxin complex was injected, the TransMTS peptide allowed for less diffusion increased toxin retention in the injection site, and ultimately a potential significantly longer duration of action. Essentially, instead of having to be reinjected every 3-4 months, RT002 could increase that time period to potentially every 6-7 months. If Revance is able to achieve this in the Phase I/II study to report out in the next few months, we – and our physician consultants – agree that this product could be highly disruptive to the existing \$2.7B global neurotoxin injectable marketplace and command a significant share. Additionally, with a significantly extended duration of action, we believe RT002 could be priced at a premium to existing injectable neurotoxins.

RT002 is currently in Phase I/II, with Phase II results to report out this spring – potentially before the Phase III results from the first pivotal RT001 study in crow's feet. Additional Phase II data could be generated and reported in 2015 at which point the Company would most likely make a decision to move into Phase III. We believe Phase III studies could start in 2015/2016 with data by 2016/2017. Then, a potential BLA filing in the US could occur in late 2017/early 2018, with a late 2018/early 2019 US approval and launch.

The initial indication for RT002 will be for the temporary reduction in the appearance of moderate to severe glabellar lines (the "11" shaped lines in between the eye brows) associated with the corrugator and/or procerus muscle activity in adult patients  $\leq 65$  years of age – the initial Botox cosmetic indication. While the goal is to significantly

increase the duration of effect, RT002 could also demonstrate a response rate and safety profile equal or superior to current injectable products. The product will be a vacuum-dried powder in a stoppered vial for reconstitution with sterile, preservative-free 0.9% sodium chloride, similar to existing injectable neurotoxin products. Also, since the product won't require mixing with a gel diluent, it should be stable at room temperature. Revance already conducted a Phase I/II study in 48 patients for RT002 with the objective of evaluating the safety and efficacy of a single administration of RT002, compared to placebo for the treatment of moderate to severe glabellar lines. The study was an open-label, dose-escalating trial with a single dose administration and 4 cohorts. The efficacy measures were investigator assessment at maximum smile, which consisted of a 4 point (0 is none; 3 is severe) Glabellar Line Severity Scale (GLSS) and a Global Aesthetic Improvement Scale (GAIS; from -3 very much worse, to 0 no change, to +3 very much improved). Dramatic improvements in all dose groups were observed and even the effect of the lowest dose appeared to be superior to current, approved injectables. 98% and 67% of subjects had a 1 and 2 point improvement on the GLSS at maximum frown at week 4. Importantly, RT002 was well-tolerated with no safety concerns, minimal AEs, and no reported ptosis. We now await results from the next Phase I/II study that will analyze duration of effect, which should report out this spring.

Figure 1 RT002 Phase I/II Study Results (% responders; n=48)



Source: Company Reports

The image below shows the significant qualitative improvement observed with a single, lowest dose of RT002 after 4 weeks. Also qualitatively, the same subject pictured below maintained this effect up to 7 months post treatment.


Figure 2 Qualitative Phase I/II Results From The Lowest Dose (Cohort 1) of RT002 To Treat Glabellar Lines



Source: Company Reports; Cowen and Company

Supporting the concept that RT002 has the potential for a longer duration of action relative to existing injectable neurotoxins, a Toxicon publication in 2011 (H.F. Stone et al. / Toxicon 58 (2011) 159–167) demonstrated that in mice RT002 treatment resulted in an extended duration as compared to Botox by 58–100%. When using “diffusion matched doses,” RT002 treatment resulted in a 100–126% increase in duration of drug effect as compared to Botox.

Figure 3 Time Course Of Single Twitch MFG Recovery After BoNTA Treatment In Mice (Weeks 1-15)



Source: H.F. Stone et al. / Toxicon 58 (2011) 159–167

Figure 4 Revance Annual P&L

REVANCE - 2018-2020 ESTIMATED ANNUAL EPS BUILDUP (\$MM)															
2012	2019E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	CGR	Comments
U.S. RT001 Cosmetic Sales					\$30.0	\$115.0	\$230.0	\$360.0	\$415.0	\$455.0	\$495.0	\$535.0	\$570.0		- RT001 in Phase III; Launch expected in late 2017
Growth Rate						+283%	+100%	+57%	+15%	+10%	+9%	+8%	+7%		- Rapid growth expected; core patents through 2027-29, with potential 5-year ext
U.S. RT001 Therapeutic Sales						\$25.0	\$65.0	\$105.0	\$160.0	\$225.0	\$295.0	\$370.0			- RT001 in Phase I/II; Launch expected in 2019
Growth Rate							+160%	+65%	+50%	+40%	+30%	+25%			- Solid growth expected
EU RT001 Cosmetic Sales						\$15.0	\$50.0	\$105.0	\$165.0	\$190.0	\$205.0	\$225.0	\$245.0		- RT001 in Phase III; Launch expected in 2018
Growth Rate							+233%	+110%	+15%	+10%	+9%	+8%	+7%		
U.S. RT002 Cosmetic Sales															- RT002 in Phase I/II; Launch expected in 2019
Growth Rate															- Could be a competitive threat to Botox; longer duration
Total Revenue Revenues	\$0.7	\$0.0	\$0.0	\$0.0	\$0.0	\$30.0	\$190.0	\$305.0	\$690.0	\$885.0	\$805.0	\$925.0	\$1,065.0	\$1,185.0	
% Change							+333%	+135%	+74%	+29%	+18%	+15%	+14%	+12%	
Cost of Goods	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$15.0	\$23.4	\$48.8	\$74.2	\$82.2	\$80.5	\$92.5	\$105.5	\$118.5	
Gross Profit	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$15.0	\$106.6	\$256.2	\$455.8	\$602.8	\$724.5	\$832.5	\$949.5	\$1,066.5	
Gross Margin						50.0%	82.0%	84.0%	86.0%	88.0%	90.0%	90.0%	90.0%	90.0%	- Solid margins
SG&A	\$11.2	\$16.0	\$17.5	\$19.0	\$30.0	\$60.0	\$75.0	\$135.0	\$175.0	\$215.0	\$235.0	\$260.0	\$280.0	\$315.0	+14% - Salesforce expansion in 2016/2017, in preparation for RT001 launch
% of Revs						200.0%	57.7%	44.3%	33.0%	31.4%	29.2%	28.1%	26.5%	26.6%	- 100 reps@S300K adds \$30MM
R&D	\$32.7	\$34.0	\$40.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	\$50.0	-1% - Clinical trial costs in 2013 of approximately \$35MM
% of Revs						166.7%	38.5%	16.4%	9.4%	7.3%	6.2%	5.4%	4.7%	4.2%	- Additional clinical trials for RT001 indications
Operating Expenses	\$43.9	\$50.0	\$57.5	\$69.0	\$80.0	\$110.0	\$125.0	\$185.0	\$225.0	\$265.0	\$285.0	\$310.0	\$330.0	\$365.0	+8%
% of Revenues						366.7%	96.2%	60.7%	42.5%	38.7%	35.4%	33.5%	31.3%	30.8%	
Operating Income	(\$43.2)	(\$50.0)	(\$57.5)	(\$69.0)	(\$80.0)	(\$95.0)	(\$18.4)	\$71.2	\$230.8	\$337.8	\$439.5	\$522.5	\$619.5	\$701.5	NM - Operating profit expected in 2019
% Operating Margin	NM	NM	NM	NM	NM	-316.7%	-14.2%	23.3%	43.5%	49.3%	54.6%	56.5%	58.7%	59.2%	
Non-Operating Income															
Interest Income	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	
Interest Expense	(29.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Other Income	13.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Non-Operating Income	(\$15.1)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	
Pretax Income	(\$58.3)	(\$50.0)	(\$57.5)	(\$69.0)	(\$80.0)	(\$95.0)	(\$18.4)	\$71.2	\$230.8	\$337.8	\$439.5	\$522.5	\$619.5	\$701.5	NM
% of Revs	NM	NM	NM	NM	NM	NM	NM	23.3%	43.5%	49.3%	54.6%	56.5%	58.7%	59.2%	
Income Taxes								\$24.9	\$80.8	\$118.2	\$153.8	\$182.9	\$216.8	\$245.5	NM
Income Tax Rate								35.0%	35.0%	35.0%	35.0%	35.0%	35.0%	35.0%	
Net Income - Operations	(\$58.3)	(\$50.0)	(\$57.5)	(\$69.0)	(\$80.0)	(\$95.0)	(\$18.4)	\$46.3	\$150.0	\$219.6	\$285.7	\$339.6	\$402.7	\$456.0	NM
% Net Margin	NM	NM	NM	NM	NM	NM	NM	15.2%	28.3%	32.1%	35.5%	36.7%	38.2%	38.5%	
Extraordinary Items	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	
Reported Net Income	(\$58.3)	(\$50.0)	(\$57.5)	(\$69.0)	(\$80.0)	(\$95.0)	(\$18.4)	\$46.3	\$150.0	\$219.6	\$285.7	\$339.6	\$402.7	\$456.0	NM
Interest Add-Back	(\$58.3)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	
EPS (GAAP) - Before Ex. Items	(\$6.85)	(\$2.95)	(\$3.25)	(\$3.65)	(\$3.80)	(\$4.15)	(\$0.75)	\$1.70	\$5.15	\$7.10	\$8.65	\$9.70	\$10.90	\$11.70	NM - Profitable in 2018/2019 following the launch of RT001
Growth	NM	NM	NM	NM	NM	NM	-82%	NM	+203%	+38%	+22%	+12%	+12%	+7%	
EPS - Extraordinary Items	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	
EPS - Reported	(\$6.85)	(\$2.95)	(\$3.25)	(\$3.65)	(\$3.80)	(\$4.15)	(\$0.75)	\$1.70	\$5.15	\$7.10	\$8.65	\$9.70	\$10.90	\$11.70	NM
Shares - Fully Diluted (MM)	17.0	17.0	17.7	19.0	21.0	23.0	25.0	27.0	29.0	31.0	33.0	35.0	37.0	39.0	- Diluted shares; assuming some onward dilution from options

Source: Cowen and Company

Figure 5 US Cosmetic Neurotoxin Treatment Market Build

ESTIMATED U.S. COSMETIC NEUROTOXIN INJECTABLE TREATMENT MARKET										
	2012	2013	2014E	2015E	2016E	2017E	2018E	2019E	2020E	CGR Comments
<b>Total WW Cosmetic &amp; Thera Neurotoxin Sales (MM)</b>	<b>\$2,400</b>	<b>\$2,700</b>	<b>\$3,025</b>	<b>\$3,350</b>	<b>\$3,700</b>	<b>\$4,050</b>	<b>\$4,350</b>	<b>\$4,850</b>	<b>\$4,950</b>	+9% - Allergan indicates the current WW market is \$2.7B
Growth Rate	+14%	+13%	+12%	+11%	+10%	+9%	+8%	+7%	+6%	- Total WW Neurotoxin growth has been 13% over the last year
<b>Total U.S. Cosmetic &amp; Thera Neurotoxin Sales (MM)</b>	<b>\$1,500</b>	<b>\$1,890</b>	<b>\$1,890</b>	<b>\$2,075</b>	<b>\$2,295</b>	<b>\$2,490</b>	<b>\$2,655</b>	<b>\$2,815</b>	<b>\$2,995</b>	+8% - Est that U.S. contributes 60-65% of WW toxin use
Growth Rate	+13%	+13%	+9%	+10%	+11%	+8%	+7%	+6%	+6%	- Estimated that Therapeutic growth will be higher than cosmetic
<i>Estimated U.S. Cosmetic Use % of Total U.S. Neurotoxin</i>	<i>48%</i>	<i>46%</i>	<i>45%</i>	<i>44%</i>	<i>43%</i>	<i>42%</i>	<i>41%</i>	<i>40%</i>	<i>39%</i>	- Est that roughly 46% of Neurotoxin use is Cosmetic
<b>Total U.S. Cosmetic Neurotoxin Sales (MM)</b>	<b>\$720</b>	<b>\$775</b>	<b>\$850</b>	<b>\$915</b>	<b>\$985</b>	<b>\$1,045</b>	<b>\$1,090</b>	<b>\$1,125</b>	<b>\$1,170</b>	+5% - U.S. market has been relatively healthy
Growth Rate	+11%	+8%	+10%	+8%	+8%	+6%	+4%	+3%	+4%	
Botox U.S. Cosmetic Share (AGN)	84%	79%	79%	79%	79%	79%	79%	79%	79%	- Leading treatment - market creator
Procedures (000)	5,378	5,422	5,763	6,237	6,710	7,097	7,398	7,656	7,957	- Procedure growth should continue to steadily grow
Average Cost Per Vial	\$450	\$450	\$465	\$465	\$465	\$465	\$465	\$465	\$465	- Botox just took a 3% price increase in Jan 2014
Sales (\$MM)	\$605.00	\$610.00	\$670.00	\$725.00	\$780.00	\$825.00	\$860.00	\$890.00	\$925.00	+6%
Dysport U.S. Cosmetic Share (VRX)	14%	14%	13%	13%	13%	13%	13%	13%	13%	- Valeant has taken over marketing; second to market
Procedures (000)	889	978	978	1,067	1,156	1,200	1,244	1,289	1,333	- Essentially undifferentiated product
Average Cost Per Vial	\$450	\$450	\$450	\$450	\$450	\$450	\$450	\$450	\$450	- Priced in-line with Botox
Sales (\$MM)	\$100.0	\$110.0	\$110.0	\$120.0	\$130.0	\$135.0	\$140.0	\$145.0	\$150.0	+5%
Others/Xeomin Share	2%	7%	8%	8%	8%	8%	8%	8%	8%	- Product was relaunched in January 2012
Procedures (000)	150	550	700	750	800	850	850	900	950	- Essentially undifferentiated product; currently has 5% market share
Average Cost Per Vial	\$400	\$400	\$400	\$400	\$400	\$400	\$400	\$400	\$400	- Pricing has been more aggressive
Sales (\$MM)	\$15.0	\$55.0	\$70.0	\$75.0	\$80.0	\$85.0	\$85.0	\$90.0	\$95.0	+5%
<b>Total Cosmetic Market Sales (MM)</b>	<b>\$720</b>	<b>\$775</b>	<b>\$850</b>	<b>\$915</b>	<b>\$985</b>	<b>\$1,045</b>	<b>\$1,090</b>	<b>\$1,125</b>	<b>\$1,170</b>	+5% - Growth continuing to be relatively stable
% Growth	+11%	+8%	+10%	+8%	+8%	+6%	+4%	+3%	+4%	

ESTIMATED U.S. COSMETIC TOPICAL NEUROTOXIN TREATMENT MARKET/RT001 ESTIMATED SALES										
	2012	2013	2014E	2015E	2016E	2017E	2018E	2019E	2020E	CGR Comments
<b>RT001 U.S. Cosmetic Sales</b>										
<b>Procedures/Patients</b>						<b>258</b>	<b>989</b>	<b>1,978</b>	<b>3,097</b>	- Procedure growth should grow rapidly
Average Cost						\$465	\$465	\$465	\$465	- In-line pricing with Botox and others
<b>Sales (\$MM)</b>						<b>\$90</b>	<b>\$115</b>	<b>\$230</b>	<b>\$360</b>	- Should be alone in the market for many years
<b>% of Estimated U.S. Injectable Cosmetic Neurotoxin</b>						<b>9%</b>	<b>11%</b>	<b>20%</b>	<b>37%</b>	- Estimated to reach 30%+ of U.S. Neurotoxin market by 2020
<b>Total U.S. Cosmetic Neurotoxin Market Sales (MM)</b>		<b>\$775</b>	<b>\$850</b>	<b>\$915</b>	<b>\$985</b>	<b>\$1,075</b>	<b>\$1,205</b>	<b>\$1,355</b>	<b>\$1,530</b>	+10% - Growth should be rapid given likely clinician/patient acceptance
% Growth						+9%	+12%	+12%	+13%	

Source: Cowen and Company

Figure 6 US Therapeutic Neurotoxin Treatment Market Build

ESTIMATED U.S. THERAPEUTIC NEUROTOXIN INJECTABLE TREATMENT MARKET											
	2012	2013	2014E	2015E	2016E	2017E	2018E	2019E	2020E	CGR	Comments
<b>Total WW Cosmetic &amp; Thera Neurotoxin Sales (MM)</b>	<b>\$2,400</b>	<b>\$2,700</b>	<b>\$3,025</b>	<b>\$3,350</b>	<b>\$3,700</b>	<b>\$4,050</b>	<b>\$4,350</b>	<b>\$4,650</b>	<b>\$4,950</b>	+9%	- Allergan indicates the current WW market is \$2.7B
Growth Rate	+14%	+13%	+12%	+11%	+10%	+9%	+8%	+7%	+6%		- Total WW Neurotoxin growth has been 13% over the last year
<b>Total U.S. Cosmetic &amp; Thera Neurotoxin Sales (MM)</b>	<b>\$1,500</b>	<b>\$1,690</b>	<b>\$1,890</b>	<b>\$2,075</b>	<b>\$2,295</b>	<b>\$2,490</b>	<b>\$2,655</b>	<b>\$2,815</b>	<b>\$2,995</b>	+8%	- Est that U.S. contributes 60-65% of WW toxin use
Growth Rate	+13%	+13%	+9%	+10%	+11%	+8%	+7%	+6%	+6%		- Estimated that Therapeutic growth will be higher than cosmetic
<i>Estimated U.S. Therapeutic Use % of Total U.S. Neurotoxin</i>	52%	54%	55%	56%	57%	58%	59%	60%	61%		- Est that roughly 54% of Neurotoxin use is Therapeutic
<b>Total U.S. Therapeutic Neurotoxin Sales (MM)</b>	<b>\$780</b>	<b>\$915</b>	<b>\$1,040</b>	<b>\$1,180</b>	<b>\$1,310</b>	<b>\$1,445</b>	<b>\$1,585</b>	<b>\$1,690</b>	<b>\$1,825</b>	+10%	- U.S. market has been relatively healthy
Growth Rate	+16%	+17%	+14%	+12%	+13%	+10%	+8%	+8%	+8%		- Estimated that Therapeutic growth will be higher than cosmetic
Botox U.S. Therapeutic Share (AGN)	88%	85%	85%	85%	85%	85%	85%	85%	85%		- Leading treatment - market creator
Procedures (000)	761	867	952	1,059	1,199	1,323	1,430	1,543	1,667		- Procedure growth should continue to steadily grow
Average Cost Per Vial	\$450	\$450	\$465	\$465	\$465	\$465	\$465	\$465	\$465		- Botox just took a 3% price increase in Jan 2014
Sales (\$MM)	\$685.00	\$780.00	\$885.00	\$985.00	\$1,115.00	\$1,230.00	\$1,330.00	\$1,435.00	\$1,550.00	+10%	
Dysport U.S. Therapeutic Share (VRX)	13%	15%	15%	15%	15%	15%	15%	15%	15%		- Valeant has taken over marketing; second to market
Procedures (000)	61	78	78	78	78	78	78	78	78		- Essentially undifferentiated product
Average Cost Per Vial	\$450	\$450	\$450	\$450	\$450	\$450	\$450	\$450	\$450		- Priced in-line with Botox
Sales (\$MM)	\$55.00	\$70.00	\$70.00	\$70.00	\$70.00	\$70.00	\$70.00	\$70.00	\$70.00	+0%	
Others/Xeomin Share											
Procedures (000)											
Average Cost Per Vial											
Sales (\$MM)											
<b>Total Cosmetic Market Sales (MM)</b>	<b>\$780</b>	<b>\$915</b>	<b>\$1,040</b>	<b>\$1,180</b>	<b>\$1,310</b>	<b>\$1,445</b>	<b>\$1,585</b>	<b>\$1,690</b>	<b>\$1,825</b>	+10%	- Growth continuing to be relatively stable
% Growth	+16%	+17%	+14%	+12%	+13%	+10%	+8%	+8%	+8%		
ESTIMATED U.S. THERAPEUTIC TOPICAL NEUROTOXIN TREATMENT MARKET/RT001 ESTIMATED SALES											
	2012	2013	2014E	2015E	2016E	2017E	2018E	2019E	2020E	CGR	Comments
<b>RT001 U.S. Therapeutic Sales</b>											
<b>Procedures/Patients</b>								27	70		- Procedure growth should grow rapidly
Average Cost								\$465	\$465		- In-line pricing with Botox and others
<b>Sales (\$MM)</b>								<b>\$25</b>	<b>\$65</b>		- Should be alone in the market for many years
<b>% of Estimated U.S. Injectable Cosmetic Neurotoxin</b>								<b>1%</b>	<b>4%</b>		- Estimated to reach ~5% of U.S. Neurotoxin market by 2020
<b>Total U.S. Cosmetic Neurotoxin Market Sales (MM)</b>	<b>\$780</b>	<b>\$915</b>	<b>\$1,040</b>	<b>\$1,180</b>	<b>\$1,310</b>	<b>\$1,445</b>	<b>\$1,585</b>	<b>\$1,715</b>	<b>\$1,890</b>	+10%	- Growth should be rapid given likely clinician/patient acceptance
% Growth	+16%	+17%	+14%	+12%	+13%	+10%	+8%	+10%	+10%		

Source: Cowen and Company



## *Valuation Methodology And Risks*

---

### **Valuation Methodology**

---

#### **Pharmaceuticals/Specialty**

For our valuation methodology, we arrive at fair value utilizing a discounted cash flow (DCF) approach to derive our 12-month price target.

### **Investment Risks**

---

#### **Pharmaceuticals/Specialty**

**Risks include:** (1) growing competitive dynamics in the specialty pharmaceuticals space; (2) the ability of management to execute on external growth by successfully acquiring new strategic, accretive products; (3) the ability to grow organically and keep the product pipeline robust; (4) potential regulatory delays, rejections, or failures of pipeline products; (5) economic sensitivity of any self-pay products or weakening consumer demand; (6) domestic or international pricing pressures for marketed products; and (7) failure to execute on new product launches.

#### **Risks To The Price Target**

---

Revance is a development-stage specialty pharmaceutical company and with that carries risk. Failure to successfully develop RT001 could result in a significant decrease to our valuation.

# Addendum

## Stocks Mentioned In Important Disclosures

Ticker	Company Name
RVNC	Revance

## Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

## Important Disclosures

Cowen and Company, LLC and/or its affiliates make a market in the stock of Revance securities.

Revance has been client(s) of Cowen and Company, LLC in the past 12 months.

Cowen and Company, LLC and/or its affiliates expect to receive, or intend to seek, compensation for investment banking services in the next 3 months from Revance.

Revance is or was in the past 12 months a client of Cowen and Company, LLC; during the past 12 months, Cowen and Company, LLC provided IB services.

Cowen and Company, LLC and/or its affiliates received in the past 12 months compensation for investment banking services from Revance.

Cowen and Company, LLC and/or its affiliates managed or co-managed a public offering of Revance within the past twelve months.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

## Disclaimer

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research can be obtained on the Firm's client website, <https://cowenlibrary.bluematrix.com/client/library.jsp>.

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure website at <https://cowen.bluematrix.com/sellside/Disclosures.action>.

**Price Targets:** Cowen and Company, LLC assigns price targets on all covered companies unless noted otherwise. The price target for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. The price targets in this report should be considered in the context of all prior published Cowen and Company, LLC research reports (including the disclosures in any such report or on the Firm's disclosure website), which may or may not include price targets, as well as developments relating to the issuer, its industry and the financial markets. For price target valuation methodology and risks associated with the achievement of any given price target, please see the analyst's research report publishing such targets.

**Notice to UK Investors:** This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

### Copyright, User Agreement and other general information related to this report

© 2014 Cowen and Company, LLC. Member NYSE, FINRA and SIPC. All rights reserved. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets). All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

**Cowen and Company, LLC. New York** (646) 562-1000 **Boston** (617) 946-3700 **San Francisco** (415) 646-7200 **Chicago** (312) 577-2240 **Cleveland** (440) 331-3531 **Atlanta** (866) 544-7009 **London** (affiliate) 44-207-071-7500

### COWEN AND COMPANY RATING DEFINITIONS

#### Cowen and Company Rating System effective May 25, 2013

**Outperform (1):** The stock is expected to achieve a total positive return of at least 15% over the next 12 months

**Market Perform (2):** The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

**Underperform (3):** Stock is expected to achieve a total negative return of at least 10% over the next 12 months

**Assumption:** The expected total return calculation includes anticipated dividend yield

#### Cowen and Company Rating System until May 25, 2013

**Outperform (1):** Stock expected to outperform the S&P 500

**Neutral (2):** Stock expected to perform in line with the S&P 500

**Underperform (3):** Stock expected to underperform the S&P 500

**Assumptions:** Time horizon is 12 months; S&P 500 is flat over forecast period

#### Cowen Securities, formerly known as Dahlman Rose & Company, Rating System until May 25, 2013

**Buy** – The fundamentals/valuations of the subject company are improving and the investment return is expected to be 5 to 15 percentage points higher than the general market return

**Sell** – The fundamentals/valuations of the subject company are deteriorating and the investment return is expected to be 5 to 15 percentage points lower than the general market return

**Hold** – The fundamentals/valuations of the subject company are neither improving nor deteriorating and the investment return is expected to be in line with the general market return

## Cowen And Company Rating Definitions

### Distribution of Ratings/Investment Banking Services (IB) as of 12/31/13

Rating	Count	Ratings Distribution	Count	IB Services/Past 12 Months
Buy (a)	415	59.20%	68	16.39%
Hold (b)	270	38.52%	4	1.48%
Sell (c)	16	2.28%	1	6.25%

(a) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions. (b) Corresponds to "Market Perform" as defined in Cowen and Company, LLC's ratings definitions. (c) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions.

Note: "Buy", "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA and NYSE regulations.

### Revance Rating History as of 03/07/2014

powered by: BlueMatrix



#### Legend for Price Chart:

I = Initiation | 1 = Outperform | 2 = Market Perform | 3 = Underperform | UR = Price Target Under Review | T = Terminated Coverage | \$xx = Price Target | NA = Not Available

## Points Of Contact

### Reaching Cowen

#### Main U.S. Locations

**New York**

599 Lexington Avenue  
New York, NY 10022  
646.562.1000  
800.221.5616

**Boston**

Two International Place  
Boston, MA 02110  
617.946.3700  
800.343.7068

**Cleveland**

20006 Detroit Road  
Suite 100  
Rocky River, OH 44116  
440.331.3531

**San Francisco**

555 California Street, 5th Floor  
San Francisco, CA 94104  
415.646.7200  
800.858.9316

**Atlanta**

3399 Peachtree Road NE  
Suite 417  
Atlanta, GA 30326  
866.544.7009

**Chicago**

181 West Madison Street  
Suite 1925  
Chicago, IL 60602  
312.577.2240

**Houston**

600 Travis Street  
Suite 1970  
Houston, TX 77002  
281.657.6800

#### International Locations

**Cowen International  
Limited****London**

1 Snowden Street - 11th Floor  
London EC2A 2DQ  
United Kingdom  
44.20.7071.7500

**Cowen and Company (Asia)  
Limited****Hong Kong**

Suite 1401 Henley Building  
No. 5 Queens Road Central  
Central, Hong Kong  
852 3752 2333

